small nuclear ribonucleoprotein D2 polypeptideGenealiases: SMD2 · SNRPD1 · Sm-D2
Q-omics provides the consensus-scored SNRPD2 profile across patient tissues and cancer cell-line models. SNRPD2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SNRPD2 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, SNRPD2 protein abundance shows 34,173 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, KIRC, and GBM as cancer lineages where SNRPD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPD2 survival associations across molecular data types. SNRPD2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPD2 RNA expression–survival associations across cancer types. High SNRPD2 expression shows unfavorable associations in LIHC, KIRP, ACC, UVM, LGG and SKCM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SNRPD2 RNA expression.
This table summarizes SNRPD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SNRPD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPD2 shows higher tumor expression in KIRC, COAD, BLCA, KIRP, LIHC and HNSC. The KIRC box plot shows higher SNRPD2 RNA expression in tumor versus normal tissue (log2 FC = +0.820, t-test p < 0.001).
This table shows molecular features associated with SNRPD2 in patient tissues and cancer cell lines. In patient samples, SNRPD2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SNRPD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
